Pathological gambling in Parkinson's disease-a review of the literature

Movement Disorders

Volumn 26, Issue 11, 2011, Pages 1976-1984

  Djamshidian, Atbin ^a   Cardoso, Francisco ^b   Grosset, Donald ^c   Bowden Jones, Henrietta ^d,e   Lees, Andrew J ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^c SOUTHERN GENERAL HOSPITAL   (United Kingdom)

^d National Problem Gambling Clinic   (United Kingdom)

^e IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

Adverse effects; Compulsions; Dopamine agonists; Impulse control; Parkinson's disease; Pathological gambling

Indexed keywords

AMANTADINE; LEVODOPA; MIRTAZAPINE; MONOAMINE OXIDASE B INHIBITOR; PRAMIPEXOLE; RACLOPRIDE C 11; REBOXETINE; TOPIRAMATE; VENLAFAXINE; ZONISAMIDE;

ANTISOCIAL BEHAVIOR; COGNITIVE DEFECT; COGNITIVE THERAPY; DEPRESSION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; DYSKINESIA; EATING DISORDER; FUNCTIONAL MAGNETIC RESONANCE IMAGING; HUMAN; MONOTHERAPY; MOOD CHANGE; PARKINSON DISEASE; PATHOLOGICAL GAMBLING; PHENOMENOLOGY; POSITRON EMISSION TOMOGRAPHY; PREVALENCE; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SLEEP DISORDER; SUBSTANCE ABUSE;

BRAIN; COGNITION DISORDERS; DOPAMINE AGONISTS; GAMBLING; HISTORY, 19TH CENTURY; HUMANS; MALE; MIDDLE AGED; PARKINSON DISEASE; PUBMED; RISK FACTORS;

EID: 80052969523     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.23821     Document Type: Review

References (103)

1. Arnold P. The Encyclopedia of Gambling. Chartwell Books; 1977.
2. Flemming A. Something for Nothing: A History of Gambling. New York: Delacorte Press; 1978.
3. Kelley AE, Schochet T, Landry CF. Risk taking and novelty seeking in adolescence: introduction to part I. Ann N Y Acad Sci. 2004; 1021: 27-32.
4. Korn DA, Shaffer HJ. Gambling and the health of the public: adopting a public health perspective. J Gambl Stud. 1999; 15: 289-365.
5. Langer EJ. The illusion of control. J Pers Soc Psychol. 1975; 32: 311-328.
6. Wardle H, Sproston K, Orford J, et al. British Gambling Prevalence Survey. London: Stationary Office; 2007.
7. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (4th ed., text rev.). Washington, DC; 2000.
8. Shaffer HJ, Hall MN, Vander Bilt J. Estimating the prevalence of disordered gambling behavior in the United States and Canada: a research synthesis. Am J Public Health. 1999; 89: 1369-1376.
9. Weintraub D, Koester J, Potenza MN, et al. Impulse control disorders in Parkinson disease: a cross-sectional study of 3090 patients. Arch Neurol. 2010; 67: 589-595.
10. Seedat S, Kesler S, Niehaus DJ, Stein DJ. Pathological gambling behaviour: emergence secondary to treatment of Parkinson's disease with dopaminergic agents. Depress Anxiety. 2000; 11: 185-186.
11. Welte JW, Barnes GM, Wieczorek WF, Tidwell MC, Parker JC. Risk factors for pathological gambling. Addict Behav. 2004; 29: 323-335.
12. Gallagher DA, O'Sullivan SS, Evans AH, Lees AJ, Schrag A. Pathological gambling in Parkinson's disease: risk factors and differences from dopamine dysregulation. An analysis of published case series. Mov Disord. 2007; 22: 1757-1763.
13. Cilia R, Siri C, Marotta G, et al. Functional abnormalities underlying pathological gambling in Parkinson disease. Arch Neurol. 2008; 65: 1604-611.
14. Griffiths M. Gambling Technologies: Prospects for Problem Gambling. J Gambl Stud. 1999; 15: 265-283.
15. Voon V, Hassan K, Zurowski M, et al. Prospective prevalence of pathologic gambling and medication association in Parkinson disease. Neurology. 2006; 66: 1750-1752.
16. Housden CR, O'Sullivan SS, Joyce EM, Lees AJ, Roiser JP. Intact Reward learning but elevated delay discounting in Parkinson's disease patients with impulsive-compulsive spectrum behaviors. Neuropsychopharmacology. 2010; 35: 2155-2164.
17. Voon V, Reynolds B, Brezing C, et al. Impulsive choice and response in dopamine agonist-related impulse control behaviors. Psychopharmacology (Berl). 2009; 207: 645-659.
18. Avanzi M, Baratti M, Cabrini S, Uber E, Brighetti G, Bonfa F. Prevalence of pathological gambling in patients with Parkinson's disease. Mov Disord. 2006; 21: 2068-2072.
19. Grosset KA, Macphee G, Pal G, et al. Problematic gambling on dopamine agonists: Not such a rarity. Mov Disord. 2006; 21: 2206-2208.
20. Singh A, Kandimala G, Dewey RB Jr, O'suilleabhain P. Risk factors for pathologic gambling and other compulsions among Parkinson's disease patients taking dopamine agonists. J Clin Neurosci. 2007; 14: 1178-1181.
21. Wicks P, MacPhee GJ. Pathological gambling amongst Parkinson's disease and ALS patients in an online community (PatientsLikeMe.com). Mov Disord. 2009; 24: 1085-1088.
22. Lee JY, Kim JM, Kim JW, et al. Association between the dose of dopaminergic medication and the behavioral disturbances in Parkinson disease. Parkinsonism Relat Disord. 2009; 16: 202-207.
23. Fan W, Ding H, Ma J, Chan P. Impulse control disorders in Parkinson's disease in a Chinese population. Neurosci Lett. 2009; 465: 6-9.
24. Molina JA, Sainz-Artiga MJ, Fraile A, et al. Pathologic gambling in Parkinson's disease: a behavioral manifestation of pharmacologic treatment? Mov Disord. 2000; 15: 869-872.
25. Healy DG. Did Géricault's "Madwoman Obsessed With Gambling" have Parkinson's disease? Mov Disord. 2007; 22: 1069-1070.
26. O'Sullivan SS, Djamshidian A, Ahmed Z, et al. Impulsive-compulsive spectrum behaviors in pathologically confirmed progressive supranuclear palsy. Mov Disord. 2010; 25: 638-642.
27. Ondo WG, Lai D. Predictors of impulsivity and reward seeking behavior with dopamine agonists. Parkinsonism Relat Disord. 2008; 14: 28-32.
28. Falhammar H, Yarker JY. Pathological gambling and hypersexuality in cabergoline-treated prolactinoma. Med J Aust. 2009; 190: 97.
29. Holman AJ. Impulse control disorder behaviors associated with pramipexole used to treat fibromyalgia. J Gambl Stud. 2009; 25: 425-431.
30. Ardouin C, Voon V, Worbe Y, et al. Pathological gambling in Parkinson's disease improves on chronic subthalamic nucleus stimulation. Mov Disord. 2006; 21: 1941-1946.
31. Solla P, Cannas A, Floris GL, et al. Behavioral, neuropsychiatric and cognitive disorders in Parkinson's disease patients with and without motor complications. Prog Neuropsychopharmacol Biol Psychiatry. 2011 [Epub ahead of print].
32. Drapier D, Drapier S, Sauleau P, et al. Pathological gambling secondary to dopaminergic therapy in Parkinson's disease. Psychiatry Res. 2006; 144: 241-244.
33. Wingo TS, Evatt M, Scott B, Freeman A, Stacy M. Impulse control disorders arising in 3 patients treated with rotigotine. Clin Neuropharmacol. 2009; 32: 59-62.
34. Gerlach M, Double K, Arzberger T, Leblhuber F, Tatschner T, Riederer P. Dopamine receptor agonists in current clinical use: comparative dopamine receptor binding profiles defined in the human striatum. J Neural Transm. 2003; 110: 1119-1127.
35. Jenner P. A novel dopamine agonist for the transdermal treatment of Parkinson's disease. Neurology. 2005; 65(2 Suppl 1): S3-S5.
36. Higley AE, Spiller K, Grundt P, et al. PG01037, a novel dopamine D3 receptor antagonist, inhibits the effects of methamphetamine in rats. J Psychopharmacol. 2011; 25: 263-273.
37. Evans AH, Strafella AP, Weintraub D, Stacy M. Impulsive and compulsive behaviors in Parkinson's disease. Mov Disord. 2009; 24: 1561-1570.
38. Hassan A, Bower JH, Kumar N, et al. Dopamine agonist-triggered pathological behaviors: surveillance in the PD clinic reveals high frequencies. Parkinsonism Relat Disord. 2011; 17: 260-264.
39. Bharmal A, Lu C, Quickfall J, Crockford D, Suchowersky O. Outcomes of patients with Parkinson disease and pathological gambling. Can J Neurol Sci. 2010; 37: 473-477.
40. Slutske WS, Caspi A, Moffitt TE, Poulton R. Personality and problem gambling: a prospective study of a birth cohort of young adults. Arch Gen Psychiatry. 2005; 62: 769-775.
41. Petry NM, Stinson FS, Grant BF. Comorbidity of DSM-IV pathological gambling and other psychiatric disorders: results from the National Epidemiologic Survey on Alcohol and Related Conditions. J Clin Psychiatry. 2005; 66: 564-574.
42. Blanco C, Hasin DS, Petry N, Stinson FS, Grant BF. Sex differences in subclinical and DSM-IV pathological gambling: results from the National Epidemiologic Survey on Alcohol and Related Conditions. Psychol Med. 2006; 36: 943-953.
43. Voon V, Thomsen T, Miyasaki JM, et al. Factors associated with dopaminergic drug-related pathological gambling in Parkinson disease. Arch Neurol. 2007; 64: 212-216.
44. Siri C, Cilia R, De Gaspari D, et al. Cognitive status of patients with Parkinson's disease and pathological gambling. J Neurol. 2010; 257: 247-252.
45. Bearn J, Evans A, Kelleher M, Turner K, Lees A. Recognition of a dopamine replacement therapy dependence syndrome in Parkinson's disease: a pilot study. Drug Alcohol Depend 2004; 76: 305-310.
46. Evans AH, Lawrence AD, Potts J, et al. Relationship between impulsive sensation seeking traits, smoking, alcohol and caffeine intake, and Parkinson's disease. J Neurol Neurosurg Psychiatry. 2006; 77: 317-321.
47. Shahed J, Davidson T, Jankovic J. Craving sweets in Parkinson's disease. Mov Disord. 2006; 21: S599.
48. Nirenberg MJ, Waters C. Compulsive eating and weight gain related to dopamine agonist use. Mov Disord. 2006; 21: 524-529.
49. Lange LA, Kampov-Polevoy AB, Garbutt JC. Sweet liking and high novelty seeking: Independent phenotypes associated with alcohol-related problems. Alcohol Alcohol. 2010; 45: 431-436.
50. Ibanez A, Blanco C, Perez de Castro I, Fernandez-Piqueras J, Saiz-Ruiz J. Genetics of pathological gambling. J Gambl Stud. 2003; 19: 11-22.
51. Comings DE, Gonzalez N, Wu S, et al. Studies of the 48 bp repeat polymorphism of the DRD4 gene in impulsive, compulsive, addictive behaviors: Tourette syndrome, ADHD, pathological gambling, and substance abuse. Am J Med Genet. 1999; 88: 358-368.
52. Eisen SA, Slutske WS, Lyons MJ, et al. The genetics of pathological gambling. Semin Clin Neuropsychiatry. 2001; 6: 195-204.
53. da Silva Lobo DS, Vallada HP, Knight J, et al. Dopamine genes and pathological gambling in discordant sib-pairs. J Gambl Stud. 2007; 23: 421-433.
54. Lobo DS, Souza RP, Tong RP, et al. Association of functional variants in the dopamine D2-like receptors with risk for gambling behaviour in healthy Caucasian subjects. Biol Psychol. 2010; 85: 33-37.
55. Comings DE, Gade R, Muhleman D, et al. Exon and intron variants in the human tryptophan 2, 3-dioxygenase gene: potential association with Tourette syndrome, substance abuse and other disorders. Pharmacogenetics. 1996; 6: 307-318.
56. Foltynie T, Lewis SG, Goldberg TE, et al. The BDNF Val66Met polymorphism has a gender specific influence on planning ability in Parkinson's disease. J Neurol. 2005; 252: 833-838.
57. Vandenbergh DJ, Rodriguez LA, Miller IT, Uhl GR, Lachman HM. High-activity catechol-O-methyltransferase allele is more prevalent in polysubstance abusers. Am J Med Genet. 1997; 74: 439-442.
58. Rossi M, Gerschcovich ER, de Achaval D, et al. Decision-making in Parkinson's disease patients with and without pathological gambling. Eur J Neurol. 2010; 17: 97-102.
59. Cunningham-Williams RM, Cottler LB, Compton WM 3rd, Spitznagel EL. Taking chances: problem gamblers and mental health disorders--results from the St. Louis Epidemiologic Catchment Area Study. Am J Public Health. 1998; 88: 1093-1096.
60. Djamshidian A, O'Sullivan S, Lees A, Averbeck BB. Novelty seeking in Parkinson's disease. Neuropsychologia. 2011 [Epub ahead of print].
61. Djamshidian A, Jha A, O'Sullivan SS, et al. Risk and learning in impulsive and nonimpulsive patients with Parkinson's disease. Mov Disord. 2010; 25: 2203-2210.
62. Poletti M, Frosini D, Lucetti C, Del Dotto P, Ceravolo R, Bonuccelli U. Decision making in de novo Parkinson's disease. Mov Disord. 2010; 25: 1432-1436.
63. Djamshidian A, O'Sullivan SS, Lees A, Averbeck BB. Stroop test performance in impulsive and non impulsive patients with Parkinson's disease. Parkinsonism Relat Disord. 2011; 17: 212-214.
64. Djamshidian A, O'Sullivan SS, Doherty K, Lees AJ, Averbeck BB. Altruistic punishment in patients with Parkinson's disease with and without impulsive behaviour. Neuropsychologia. 2011; 49: 103-107.
65. Voon V, Pessiglione M, Brezing C, et al. Mechanisms underlying dopamine-mediated reward bias in compulsive behaviors. Neuron. 2010; 65: 135-142.
66. World Health Organization. International Statistical Classification of Diseases and Related Health Problems. Geneva, Switzerland; 1992.
67. Castellani B, Rugle L. A comparison of pathological gamblers to alcoholics and cocaine misusers on impulsivity, sensation seeking, and craving. Int J Addict. 1995; 30: 275-289.
68. Hall GW, Carriero NJ, Takushi RY, Montoya ID, Preston KL, Gorelick DA. Pathological gambling among cocaine-dependent outpatients. Am J Psychiatry. 2000; 157: 1127-1133.
69. Zack M, Poulos CX. Amphetamine primes motivation to gamble and gambling-related semantic networks in problem gamblers. Neuropsychopharmacology. 2004; 29: 195-207.
70. Dowling N, Smith D, Thomas T. Electronic gaming machines: are they the 'crack-cocaine' of gambling? Addiction. 2005; 100: 33-45.
71. Wray I, Dickerson MG. Cessation of high frequency gambling and "withdrawal" symptoms. Br J Addict. 1981; 76: 401-405.
72. Kish SJ, Shannak K, Hornykiewicz O. Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease. Pathophysiologic and clinical implications. N Engl J Med. 1988; 318: 876-880.
73. Gotham AM, Brown RG, Marsden CD. Levodopa treatment may benefit or impair "frontal" function in Parkinson's disease. Lancet. 1986; 2: 8970-8511.
74. Swainson R, Rogers RD, Sahakian BJ, Summers BA, Polkey CE, Robbins TW. Probabilistic learning and reversal deficits in patients with Parkinson's disease or frontal or temporal lobe lesions: possible adverse effects of dopaminergic medication. Neuropsychologia. 2000; 38: 596-612.
75. Jenner P. Molecular mechanisms of L-DOPA-induced dyskinesia. Nat Rev Neurosci. 2008; 9: 665-677.
76. Ye Z, Hammer A, Camara E, Munte TF. Pramipexole modulates the neural network of reward anticipation. Hum Brain Mapp. 2011; 35: 800-811.
77. van Eimeren T, Ballanger B, Pellecchia G, Miyasaki JM, Lang AE, Strafella AP. Dopamine agonists diminish value sensitivity of the orbitofrontal cortex: a trigger for pathological gambling in Parkinson's disease? Neuropsychopharmacology. 2009; 34: 2758-2766.
78. Frank MJ, O'Reilly RC. A mechanistic account of striatal dopamine function in human cognition: psychopharmacological studies with cabergoline and haloperidol. Behav Neurosci. 2006; 120: 497-517.
79. Seguin JR, Arseneault L, Tremblay R. The contribution of "cool" and "hot" components of decision-making in adolescence: implications for psychopathology. Cogn Dev. 2007; 22: 530-543.
80. O'Sullivan SS, Wu K, Politis M, et al. Cue-induced striatal dopamine release in Parkinson's disease-associated impulsive-compulsive behaviours. Brain. 2011; 134: 969-978.
81. Steeves TD, Miyasaki J, Zurowski M, et al. Increased striatal dopamine release in Parkinsonian patients with pathological gambling: a [11C] raclopride PET study. Brain. 2009; 132: 1376-1385.
82. Evans AH, Pavese N, Lawrence AD, et al. Compulsive drug use linked to sensitized ventral striatal dopamine transmission. Ann Neurol. 2006; 59: 852-858.
83. Dalley JW, Fryer TD, Brichard L, et al. Nucleus accumbens D2/3 receptors predict trait impulsivity and cocaine reinforcement. Science. 2007; 315: 1267-1270.
84. Nader MA, Morgan D, Gage HD, et al. PET imaging of dopamine D2 receptors during chronic cocaine self-administration in monkeys. Nat Neurosci. 2006; 9: 1050-1056.
85. van Eimeren T, Pellecchia G, Cilia R, et al. Drug-induced deactivation of inhibitory networks predicts pathological gambling in PD. Neurology. 2010; 75: 1711-1716.
86. Frosini D, Pesaresi I, Cosottini M, et al. Parkinson's disease and pathological gambling: results from a functional MRI study. Mov Disord. 2010; 25: 2449-2453.
87. Macphee GJ, Copeland C, Stewart D, Grosset K, Grosset DG. Clinical follow up of pathological gambling in Parkinson's disease in the West Scotland study. Mov Disord. 2009; 24: 2430-2431.
88. Grosset DG, Cardoso F, Lees A. Dopamine agonists vs levodopa in impulse control disorders. Arch Neurol. 2011; 68: 544-545.
89. Rabinak CA, Nirenberg MJ. Dopamine agonist withdrawal syndrome in Parkinson disease. Arch Neurol. 2010; 67: 58-63.
90. Hodgins DC, Petry NM. Cognitive and behavioral treatments. In Grant JE, Potenza MN, editors Pathological gambling: a clinical guide to treatment Washington, DC, American Psychiatric Press; 2004: 169-188.
91. O'Sullivan SS, Loane CM, Lawrence AD, Evans AH, Piccini P, Lees AJ. Sleep disturbance and impulsive-compulsive behaviours in Parkinson's disease. J Neurol Neurosurg Psychiatry. 2011; 82: 620-622.
92. Menza M, Dobkin RD, Marin H, et al. A controlled trial of antidepressants in patients with Parkinson disease and depression. Neurology. 2009; 72: 886-892.
93. Skapinakis P, Bakola E, Salanti G, Lewis G, Kyritsis AP, Mavreas V. Efficacy and acceptability of selective serotonin reuptake inhibitors for the treatment of depression in Parkinson's disease: a systematic review and meta-analysis of randomized controlled trials. BMC Neurol. 2010; 10: 49.
94. Blanco C, Petkova E, Ibanez A, Saiz-Ruiz J. A pilot placebo-controlled study of fluvoxamine for pathological gambling. Ann Clin Psychiatry. 2002; 14: 9-15.
95. Black DW, Arndt S, Coryell WH, et al. Bupropion in the treatment of pathological gambling: a randomized, double-blind, placebo-controlled, flexible-dose study. J Clin Psychopharmacol. 2007; 27: 143-150.
96. Sevincok L, Akoglu A, Akyol A. Quetiapine in a case with Parkinson disease and pathological gambling. J Clin Psychopharmacol. 2007; 27: 107-108.
97. McElroy SL, Nelson EB, Welge JA, Kaehler L, Keck PE, Jr. Olanzapine in the treatment of pathological gambling: a negative randomized placebo-controlled trial. J Clin Psychiatry. 2008; 69: 433-440.
98. Bermejo PE. Topiramate in managing impulse control disorders in Parkinson's disease. Parkinsonism Relat Disord. 2008; 14: 448-449.
99. Bermejo PE, Ruiz-Huete C, Anciones B. Zonisamide in managing impulse control disorders in Parkinson's disease. J Neurol. 2010; 257: 1682-1685.
100. Kashihara K, Imamura T. Amantadine may reverse punding in Parkinson's disease--observation in a patient. Mov Disord. 2008; 23: 129-130.
101. Thomas A, Bonanni L, Gambi F, Di Iorio A, Onofrj M. Pathological gambling in Parkinson disease is reduced by amantadine. Ann Neurol. 2010; 68: 400-404.
102. Weintraub D, Sohr M, Potenza MN, et al. Amantadine use associated with impulse control disorders in Parkinson disease in cross-sectional study. Ann Neurol. 2010; 68: 963-968.
103. Lee JY, Kim HJ, Jeon BS. Is pathological gambling in Parkinson's disease reduced by amantadine? Ann Neurol. 2011; 69: 213-214; author reply 214-215.